Nanobac Pharmaceuticals, Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNBP research report →
Companywww.nanobac.com
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO.
- CEO
- John Stanton
- IPO
- 1994
- Employees
- 1
- HQ
- Tampa, FL, US
Price Chart
Valuation
- Market Cap
- $24.95K
- P/E
- 0.00
- P/S
- 1.42
- P/B
- 0.00
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 17.60%
- Op Margin
- 27891.78%
- Net Margin
- -37319.74%
- ROE
- 357.99%
- ROIC
- 106.93%
Growth & Income
- Revenue
- $17.62K · -92.17%
- Net Income
- $-6,576,111 · -32.23%
- EPS
- $0.00 · 100.00%
- Op Income
- $4.91M
- FCF YoY
- 64.88%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -35.70
- Avg Volume
- 10.76K
Get TickerSpark's AI analysis on NNBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NNBP Coverage
We haven't published any research on NNBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NNBP Report →